Who makes zolpidem-MR (SL800750)?

zolpidem-MR (SL800750) is developed by Sanofi.

What development phase is zolpidem-MR (SL800750) in?

zolpidem-MR (SL800750) is in Phase 3.

Last reviewed 2026-05-13 · How we verify

zolpidem-MR (SL800750)

Sanofi · Phase 3 active Small molecule

At a glance

Generic name	zolpidem-MR (SL800750)
Sponsor	Sanofi
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia (PHASE3)
Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

zolpidem-MR (SL800750) CI brief — competitive landscape report
zolpidem-MR (SL800750) updates RSS · CI watch RSS
Sanofi portfolio CI